New Horizons in Alzheimer’s Disease

New Horizons in Alzheimer’s Disease

New Horizons in Alzheimer’s Disease

New agents to treat Alzheimer’s disease are in the late stages of development. How will these emerging therapeutics shift the treatment paradigm?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Once an Alzheimer’s disease diagnosis is made, the next challenge is treatment. Dr. Alizera Atri and Dr. Marwan Sabbagh discuss the current standard of care, the clinical pipeline for Alzheimer’s disease, and the role of amyloid-beta-targeted antibodies.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Alireza Atri, MD, PhD 
    Director, Banner Sun Health Research Institute
    Banner Health
    Sun City, AZ
    Consulting Fees: Acadia, Biogen, Grifols, JOMDD (Japanese Organization for Medical Device Development), Lundbeck, Medical Care Corporation (with NIH), Novo Nordisk, Roche/Genentech, Suven
    Book Royalty: Oxford University Press (Dementia: Comprehensive Principles and Practice

    Marwan Noel Sabbagh, MD, FAAN, CCRI 
    Director, Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, NV
    Royalty: Harper Collins
    Consulting Fees: Acadia, Alzheon, Biogen, Cortexyme, Danone, Regeneron, Roche-Genentech, Stage 2 Innovations
    Contracted Research: NIH, Keep Memory Alive
    Stocks: Athira, Brain Health Inc., NeuroReserve Inc., NeuroTau, Optimal Cognitive Health Compnay, uMETHOD Health, Versanum Inc.
    Speakers Bureau: Health and Wellnesss Partners, Joyce Knapp Communications

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Nick Lombardi has disclosed Ownership interest: Vertex Pharmaceuticals.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the clinical trial landscape for AD
    • Discuss the signs and symptoms of early AD
  • Target Audience

    This activity is designed to meet the educational needs of neurologists, neurology nurses, nurse practitioners, physician assistants and other healthcare providers that treat patients with Alzheimer’s disease.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by independent educational grants from Biogen and Eisai.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free